Antistreptokinase antibodies before and after streptokinase therapy in patients with acute myocardial infarction from areas endemic for streptococcal infection and influence on reperfusion rates

Garg Shaila, Y. S. Chandrashekhar, Nanda Kumar, Nirmal K. Ganguly, Inder S. Anand

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

We conclude that patients with myocardial infarction from areas endemic for streptococcal infection have high levels of preexisting ASK antibodies. However, these antibodies do not appear to interfere with the efficacy of reperfusion with streptokinase. Similarly, high basal ASK antibody titers do not increase the risk of allergic reactions to streptokinase.

Original languageEnglish (US)
Pages (from-to)187-189
Number of pages3
JournalThe American Journal of Cardiology
Volume74
Issue number2
DOIs
StatePublished - Jul 15 1994

Bibliographical note

Funding Information:
From the Department of Forensic Medicine, University of Uppsala, Uppsala, Sweden, and the Department of Medicine, University of Florida College of Medicine, Gainesville, Florida. This study was supported by grants from the Swedish Medical Research Council, Stockholm, Sweden, and the American Heart Association, Florida Affiliate, St. Petersburg, Florida. Manuscript received September 10, 1993; revised manuscript received and accepted January 3, 1994.

Fingerprint Dive into the research topics of 'Antistreptokinase antibodies before and after streptokinase therapy in patients with acute myocardial infarction from areas endemic for streptococcal infection and influence on reperfusion rates'. Together they form a unique fingerprint.

Cite this